Efficacy of a Propolis-Based Syrup (FARINGEL) in Preventing Radiation-Induced Esophagitis in Locally Advanced Lung Cancer
Research conducted at Bio-Medica University, Italy, in 2018 evaluated the efficacy of a propolis-based syrup in preventing radiation-induced esophagitis in locally advanced lung cancer patients. The patients treated with concurrent chemoradiotherapy (CRT) using involved-field radiotherapy (RT) received FARINGEL at the beginning of CRT until the first follow-up. . Forty-one patients completed the protocol and were evaluated for esophagitis. The results showed that grade 2–3 esophagitis was lower (22% and 38%) in the study group than in the control group. In addition, a delay in the onset of grade ≥2 esophagitis and a lower mean number of interruption days for esophagitis were observed in the study group than in the control group. The scientists concluded propolis syrup was well-tolerated and delayed esophagitis induced by CRT for locally advanced lung cancer.*
*Ippolito, E., Floreno, B., Rinaldi, C.G., Trodella, L., Meroni, F.L., Iurato, A., D’Angelillo, R.M., Ramella, S. and Fiore, M., 2018. Efficacy of a propolis-based syrup (FARINGEL) in preventing radiation-induced esophagitis in locally advanced lung cancer. Chemotherapy, 63(2), pp.76-82.